GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Roche Holding AG (OTCPK:RHHBY) » Definitions » EV-to-EBIT

Roche Holding AG (Roche Holding AG) EV-to-EBIT

: 12.84 (As of Today)
View and export this data going back to 2002. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Roche Holding AG's Enterprise Value is $218,151 Mil. Roche Holding AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $16,991 Mil. Therefore, Roche Holding AG's EV-to-EBIT for today is 12.84.

The historical rank and industry rank for Roche Holding AG's EV-to-EBIT or its related term are showing as below:

RHHBY' s EV-to-EBIT Range Over the Past 10 Years
Min: 12.46   Med: 16.27   Max: 20.53
Current: 12.82

During the past 13 years, the highest EV-to-EBIT of Roche Holding AG was 20.53. The lowest was 12.46. And the median was 16.27.

RHHBY's EV-to-EBIT is ranked better than
63.77% of 668 companies
in the Drug Manufacturers industry
Industry Median: 16.995 vs RHHBY: 12.82

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Roche Holding AG's Enterprise Value for the quarter that ended in Dec. 2023 was $259,079 Mil. Roche Holding AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $16,991 Mil. Roche Holding AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 6.56%.


Roche Holding AG EV-to-EBIT Historical Data

The historical data trend for Roche Holding AG's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roche Holding AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.83 14.59 18.34 14.87 14.54

Roche Holding AG Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.34 - 14.87 - 14.54

Competitive Comparison

For the Drug Manufacturers - General subindustry, Roche Holding AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Roche Holding AG EV-to-EBIT Distribution

For the Drug Manufacturers industry and Healthcare sector, Roche Holding AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Roche Holding AG's EV-to-EBIT falls into.



Roche Holding AG EV-to-EBIT Calculation

Roche Holding AG's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=218150.667/16991.148
=12.84

Roche Holding AG's current Enterprise Value is $218,151 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Roche Holding AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $16,991 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Roche Holding AG  (OTCPK:RHHBY) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Roche Holding AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=16991.148/259079.2412
=6.56 %

Roche Holding AG's Enterprise Value for the quarter that ended in Dec. 2023 was $259,079 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Roche Holding AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $16,991 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Roche Holding AG EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Roche Holding AG's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Roche Holding AG (Roche Holding AG) Business Description

Address
Grenzacherstrasse 124, Basel, CHE, 4070
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Roche Holding AG (Roche Holding AG) Headlines

From GuruFocus

Roche expands long-term alliance with Sysmex

By PRNewswire 08-03-2023

Analysts Tab Veeva Systems as a Top Value Pick

By Barry Cohen 05-25-2022